Driven by Innovation & Growth
Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.
Virginia's Life Science Community By the Numbers
-
1,451 Companies
Life science companies in Virginia.
-
$8B Industry
Life Science contributes $8B to Virginia's economy.
-
26,545 People
Employed by Life Science companies in Virginia.
-
$77,848 Average Wage
Average earnings of life science workers in Virginia.
-
1,197 Clinical trials
Biopharmaceutical industry-sponsored trials in Virginia per year.
News
11/05/2024
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
Adial Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, …
10/29/2024
Kaléo Announces Chief Development Officer
Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer. Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With …
10/28/2024
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline
AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for …
Our Premium Partners
